试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-22
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
编号:NCT03422627登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:Efavaleukin Alfa
登记的停止原因(原文):Sponsor Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-22
Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain
编号:NCT03537612登记状态:提前终止企业 / 申办者:Dr. Jean A. Ouellet, MD, FRCSC
药物 / 成分:Clonidine、Morphine
登记的停止原因(原文):Do to our inability to meet recruitment targets - Sponsor stopped funding. Looking for new sponsor and protocol modifications
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-22
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
编号:NCT04028466登记状态:提前终止企业 / 申办者:St. Luke's Medical Center, Philippines
药物 / 成分:Vonoprazan、Omeprazole
登记的停止原因(原文):Budget for the study was withdrawn and discontinued
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-22
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
编号:NCT04589832登记状态:提前终止企业 / 申办者:Arkadiusz Z. Dudek, MD
药物 / 成分:PAC-1、Entrectinib
登记的停止原因(原文):This study required dose reductions to the lower dose level (Dose level -1). But this dose level (Dose level -1) was not further explored because of lack of funding.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-21
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
编号:NCT01990352登记状态:提前终止企业 / 申办者:University of Arizona
药物 / 成分:Pegylated liposomal doxorubicin
登记的停止原因(原文):The PI determined that study specimens being obtained did not yield sufficient data to analyze the prespecified outcome measures and decided to terminate the study prior to meeting enrollment goals.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-21
Chloroprocaine 3% - Epidural Anesthesia in Unplanned Caesarean Section
编号:NCT02919072登记状态:提前终止企业 / 申办者:Sintetica SA
药物 / 成分:Chloroprocaine、Ropivacaine
登记的停止原因(原文):The doctors involved in the study did not enroll any patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-21
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
编号:NCT03944902登记状态:提前终止企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Cohort 1: Dose Escalation、Cohort 2: Dose Escalation
登记的停止原因(原文):will not resume. company choosing not to continue with drug. one participant now off study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-21
Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors
编号:NCT03954704登记状态:提前终止企业 / 申办者:Gilead Sciences
药物 / 成分:Dalutrafusp alfa、mFOLFOX6 Regimen、Dalutrafusp alfa
登记的停止原因(原文):The decision to discontinue the study was made based on the totality of the clinical, pharmacokinetic, and pharmacodynamic findings. No safety concerns were observed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-21
Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
编号:NCT04247594登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Voxelotor
登记的停止原因(原文):Data will not inform further development of Voxelotor
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-18
Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome
编号:NCT01500473登记状态:提前终止企业 / 申办者:Children's Hospital Los Angeles
药物 / 成分:Desogestrel
登记的停止原因(原文):Only one subject was studied, who did not respond.
查看官方原始记录 ↗